Phase 1Completed
Assessment of Abuse Potential of Rapastinel in Humans
A Two-part, Single-dose, Randomized, Double-blind, Placebo and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Rapastinel in Healthy, Non-dependent, Adult Recreational Polydrug Users
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc (Industry)
- Enrollment
- 72 enrolled
- Conditions
- Human Abuse Potential
- Interventions
- Rapastinel; Ketamine; Placebo
- Ages
- adults
- Registry
- NCT03799900
Full record on ClinicalTrials.gov
From the registry
Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR antagonist that is a Schedule III dissociative anesthetic, and placebo in recreational polydrug users.
Primary outcomes
- Maximum effect (Emax) for "At this Moment" Drug Liking visual analog scale (VAS).
History
Last registry update
Study completion
Primary completion
Registered
Started